Isolated Limb Perfusion and Isolated Limb Infusion for Malignant Lesions of the Extremities

Current Problems in Surgery

Volumn 48, Issue 6, 2011, Pages 371-430

  Sanki, Amira ^a   Kroon, Hidde M ^b   Kam, Peter C A ^c   Thompson, John F ^d  

^a Senior Registrar in Plastic and Reconstructive Surgery   (Australia)

^b RIJNLAND HOSPITAL   (Netherlands)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CISPLATIN; CORTICOSTEROID; CREATINE KINASE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DEXAMETHASONE; ERYTHROPOIETIN; ETOPOSIDE; FOTEMUSTINE; GAMMA INTERFERON; HEPARIN; HIRUDIN; INTERFERON; MELPHALAN; PAPAVERINE; TEMOZOLOMIDE; THIOTEPA; TROPISETRON; TUMOR NECROSIS FACTOR ALPHA; VINDESINE;

ACIDOSIS; ARTERY THROMBOSIS; ARTICLE; BANDAGE; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CEREBROVASCULAR DISEASE; COMPARTMENT SYNDROME; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG FEVER; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; HUMAN; HYPERTHERMIA; HYPOTENSION; HYPOXIA; INTRAOPERATIVE PERIOD; ISOLATED LIMB INFUSION; ISOLATED LIMB PERFUSION; LEG THROMBOPHLEBITIS; LIMB DISEASE; LIMB PERFUSION; LIMB SALVAGE; LIMB TUMOR; LOW DRUG DOSE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MORBIDITY; MORTALITY; MULTIPLE ORGAN FAILURE; MYCOSIS FUNGOIDES; NAUSEA AND VOMITING; NONHUMAN; PATIENT SELECTION; PERIPHERAL NEUROPATHY; POSTOPERATIVE NAUSEA AND VOMITING; POSTOPERATIVE PERIOD; PROGNOSIS; REGIONAL PERFUSION; SARCOMA; SIDE EFFECT; SINGLE DRUG DOSE; SKIN CANCER; SOFT TISSUE SARCOMA; SURGICAL APPROACH; SURGICAL TECHNIQUE; SURVIVAL TIME; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TACHYCARDIA; THROMBOEMBOLISM; TOURNIQUET; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TUMOR REGRESSION; UNSPECIFIED SIDE EFFECT; URINE VOLUME; VEIN THROMBOSIS;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DRUG ADMINISTRATION SCHEDULE; EXTREMITIES; HUMANS; INFUSIONS, PARENTERAL; NEOPLASMS;

EID: 79955593940     PISSN: 00113840     EISSN: None     Source Type: Journal    
DOI: 10.1067/j.cpsurg.2011.02.002     Document Type: Article

References (181)

1. Creech O., Krementz E.T., Ryan R.F., et al. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958, 148:616-632.
2. Klopp C.T., Alford T.C., Bateman J., et al. Fractionated intra-arterial cancer; chemotherapy with methyl bis amine hydrochloride; a preliminary report. Ann Surg 1950, 132:811-832.
3. Cavaliere R., Ciocatto E.C., Giovanella B.C., et al. Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer 1967, 20:1351-1381.
4. Stehlin J.S., Giovanella B.C., de Ipolyi P.D., et al. Results of hyperthermic perfusion for melanoma of the extremities. Surg Gynecol Obstet 1975, 140:339-348.
5. Wieberdink J., Benckhuysen C., Braat R.P., et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982, 18:905-910.
6. Koops H.S., Vaglini M., Suciu S., et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol 1998, 16:2906-2912.
7. McMasters K.M. Isolated limb perfusion in elderly melanoma patients. Ann Surg Oncol 2002, 9:939-940.
8. Thompson J.F., de Wilt J.H. Isolated limb perfusion in the management of patients with recurrent limb melanoma: an important but limited role. Ann Surg Oncol 2001, 8:564-565.
9. Eggermont A.M., de Wilt J.H., ten Hagen T.L. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 2003, 4:429-437.
10. Olieman A.F., Lienard D., Eggermont A.M., et al. Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study. Arch Surg 1999, 134:303-307.
11. Taber S.W., Polk H.C. Mortality, major amputation rates, and leukopenia after isolated limb perfusion with phenylalanine mustard for the treatment of melanoma. Ann Surg Oncol 1997, 4:440-445.
12. van Etten B., van Geel A.N., de Wilt J.H., et al. Fifty tumor necrosis factor-based isolated limb perfusions for limb salvage in patients older than 75 years with limb-threatening soft tissue sarcomas and other extremity tumors. Ann Surg Oncol 2003, 10:32-37.
13. Vrouenraets B.C., Eggermont A.M., Hart A.A., et al. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor-alpha versus toxicity after melphalan alone. Eur J Surg Oncol 2001, 27:390-395.
14. Lindemann W., Richter S., Schilling M.K. Hirudin-based anticoagulant strategy during isolated limb perfusion in a patient with heparin-induced thrombocytopenia. Melanoma Res 2005, 15:287-290.
15. van Akkooi A.C., Golab-Schwarz H.D., Eggermont A.M., et al. Isolated limb perfusion for an irresectable melanoma recurrence in a Jehovah's witness. Eur J Cardiothorac Surg 2006, 30:408-410.
16. Chang S.Y., Alberts D.S., Farquhar D., et al. Hydrolysis and protein binding of melphalan. J Pharmacol Sci 1978, 67:682-684.
17. Thompson J.F., Lai D.T., Ingvar C., et al. Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma. Melanoma Res 1994, 4(Suppl 1):45-50.
18. Schraffordt Koops H., Lejeune F.J., Kroon B.B.R., et al. Isolated limb perfusion for melanoma: technical aspects. Textbook of Melanoma 2004, 404-409. Martin Dunitz, London. J.F. Thompson, D.L. Morton, B.B.R. Kroon (Eds.).
19. Fontijne W.P., Mook P.H., Koops H.S., et al. Improved tissue perfusion during pressure regulated hyperthermic regional isolated perfusion. A clinical study. Cancer 1985, 55:1455-1461.
20. Thompson J.F., Good P.D., Kam P.C.A. Hyperthermic isolated limb perfusion in the treatment of melanoma: technical aspects. Reg Cancer Treat 1994, 7:147-154.
21. Klaase J.M., Kroon B.B., van Geel B.N., et al. Patient- and treatment-related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities. Am J Surg 1994, 167:618-620.
22. Kroon B.B., Fraker D.L., Vrouenraets B.C., et al. Isolated limb perfusion: results and complications. Textbook of Melanoma 2004, 410-428. Martin Dunitz, London. J.F. Thompson, D.L. Morton, B.B. Kroon (Eds.).
23. Kroon B.B., Klaase J.M., van Geel B.N., et al. Results of a double perfusion schedule with melphalan in patients with melanoma of the lower limb. Eur J Cancer 1993, 29A:325-328.
24. Vrouenraets B.C., Kroon B.B., Klaase J.M., et al. Severe acute regional toxicity after normothermic or "mild" hyperthermic isolated limb perfusion with melphalan for melanoma. Melanoma Res 1995, 5:425-431.
25. Bryant P.J., Balderson G.A., Mead P., et al. Hyperthermic isolated limb perfusion for malignant melanoma: response and survival. World J Surg 1995, 19:363-368.
26. Bonifati D.M., Ori C., Rossi C.R., et al. Neuromuscular damage after hyperthermic isolated limb perfusion in patients with melanoma or sarcoma treated with chemotherapeutic agents. Cancer Chemother Pharmacol 2000, 46:517-522.
27. Fraker D.L. Management of in-transit melanoma of the extremity with isolated limb perfusion. Curr Treat Options Oncol 2004, 5:173-184.
28. Hohenberger P, Finke LH, Schlag PM. Intracompartmental pressure during hyperthermic isolated limb perfusion for melanoma and sarcoma. Eur J Surg Oncol.
29. Vrouenraets B.C., Klaase J.M., Kroon B.B., et al. Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions. Arch Surg 1995, 130:43-47.
30. Krementz E.T., Sutherland C.M., Muchmore J.H. Isolated hyperthermia chemotherapy perfusion for limb melanoma. Surg Clin North Am 1996, 76:1313-1330.
31. Clark J., Grabs A.J., Parsons P.G., et al. Melphalan uptake, hyperthermic synergism and drug resistance in a human cell culture model for the isolated limb perfusion of melanoma. Melanoma Res 1994, 4:365-370.
32. Scott R.N., Blackie R., Kerr D.J., et al. Melphalan concentration and distribution in the tissues of tumour-bearing limbs treated by isolated limb perfusion. Eur J Cancer 1992, 28A:1811-1813.
33. Krementz E.T., Carter R.D., Sutherland C.M., et al. Regional chemotherapy for melanoma. A 35-year experience. Ann Surg 1994, 220:520-534. [Discussion 534-5].
34. Siemann D.W., Chapman M., Beikirch A. Effects of oxygenation and pH on tumor cell response to alkylating chemotherapy. Int J Radiat Oncol Biol Phys 1991, 20:287-289.
35. Stratford I.J., Adams G.E., Godden J., et al. Potentiation of the anti-tumour effect of melphalan by the vasoactive agent, hydralazine. Br J Cancer 1988, 58:122-127.
36. Wu Z.Y., Smithers B.M., Roberts M.S. Tissue and perfusate pharmacokinetics of melphalan in isolated perfused rat hindlimb. J Pharmacol Exp Ther 1997, 282:1131-1138.
37. Sonneveld E.J., Vrouenraets B.C., van Geel B.N., et al. Systemic toxicity after isolated limb perfusion with melphalan for melanoma. Eur J Surg Oncol 1996, 22:521-527.
38. Thompson J.F., Malouf D.J., Merzliakov S., et al. Efficacy of single-dose ondansetron in the prevention of post-operative nausea and vomiting following isolated limb perfusion with cytotoxic agents. Reg Cancer Treat 1993, 6:177-182.
39. van Geel A.N., van Wijk J., Wieberdink J. Functional morbidity after regional isolated perfusion of the limb for melanoma. Cancer 1989, 63:1092-1096.
40. Vrouenraets B.C., Veld G.J., Nieweg O.E., et al. Long-term functional morbidity after mild hyperthermic isolated limb perfusion with melphalan. Eur J Surg Oncol 1999, 25:503-508. in't.
41. Olieman A.F., Schraffordt Koops H., Geertzen J.H., et al. Functional morbidity of hyperthermic isolated regional perfusion of the extremities. Ann Surg Oncol 1994, 1:382-388.
42. Noorda E.M., van Kreij R.H., Vrouenraets B.C., et al. The health-related quality of life of long-term survivors of melanoma treated with isolated limb perfusion. Eur J Surg Oncol 2007, 33:776-782.
43. Du Vivier A., Vonderheid E.C., Van Scott E.J., et al. Mycosis fungoides, nitrogen mustard and skin cancer. Br J Dermatol 1978, 99:61-63.
44. Lamb P.M., Menaker G.M., Moy R.L. Multiple basal cell carcinomas of the limb after adjuvant treatment of melanoma with isolated limb perfusion. J Am Acad Dermatol 1998, 38:767-768.
45. Sanki A., Kam P.C., Thompson J.F. Long-term results of hyperthermic, isolated limb perfusion for melanoma: a reflection of tumor biology. Ann Surg 2007, 245:591-596.
46. Thompson J.F., Kam P.C.A., Ramzan I., et al. Clinical pharmacokinetics of melphalan in isolated limb perfusion: compartmental modelling and moment analysis. Reg Cancer Treat 1995, 8:83-87.
47. Carswell E.A., Old L.J., Kassel R.L., et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975, 72:3666-3670.
48. Lienard D., Ewalenko P., Delmotte J.J., et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992, 10:52-60.
49. Fajardo L.F., Kwan H.H., Kowalski J., et al. Dual role of tumor necrosis factor-alpha in angiogenesis. Am J Pathol 1992, 140:539-544.
50. Lejeune F.J. Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeability. J Clin Invest 2002, 110:433-435.
51. Hoving S., Seynhaeve A.L., van Tiel S.T., et al. Early destruction of tumor vasculature in tumor necrosis factor-alpha-based isolated limb perfusion is responsible for tumor response. Anti Cancer Drugs 2006, 17:949-959.
52. de Wilt J.H., ten Hagen T.L., de Boeck G., et al. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 2000, 82:1000-1003.
53. de Wilt J.H., Manusama E.R., van Tiel S.T., et al. Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer 1999, 80:161-166.
54. Lienard D., Eggermont A.M., Kroon B.B., et al. Isolated limb perfusion in primary and recurrent melanoma: indications and results. Semin Surg Oncol 1998, 14:202-209.
55. Grunhagen D.J., de Wilt J.H., van Geel A.N., et al. Isolated limb perfusion for melanoma patients-a review of its indications and the role of tumour necrosis factor-alpha. Eur J Surg Oncol 2006, 32:371-380.
56. Hohenberger P., Latz E., Kettelhack C., et al. Pentoxifylline attenuates the systemic inflammatory response induced during isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan. Ann Surg Oncol 2003, 10:562-568.
57. Rossi C.R., Foletto M., Pilati P., et al. Isolated limb perfusion in locally advanced cutaneous melanoma. Semin Oncol 2002, 29:400-409.
58. Fraker D.L., Alexander H.R., Andrich M., et al. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol 1996, 14:479-489.
59. Martijn H., Schraffordt Koops H., Milton G.W., et al. Comparison of two methods of treating primary malignant melanomas Clark IV and V, thickness 1.5 mm and greater, localized on the extremities. Wide surgical excision with and without adjuvant regional perfusion. Cancer 1986, 57:1923-1930.
60. Franklin H.R., Schraffordt Koops H., Oldhoff J., et al. To perfuse or not to perfuse?. A retrospective comparative study to evaluate the effect of adjuvant isolated regional perfusion in patients with stage I extremity melanoma with a thickness of 1.5 mm or greater. J Clin Oncol 1988, 6:701-708.
61. Edwards M.J., Soong S.J., Boddie A.W., et al. Isolated limb perfusion for localized melanoma of the extremity. A matched comparison of wide local excision with isolated limb perfusion and wide local excision alone. Arch Surg 1990, 125:317-321.
62. Thompson J.F., Hunt J.A., Shannon K.F., et al. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg 1997, 132:903-907.
63. Hafstrom L., Rudenstam C.M., Blomquist E., et al. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. J Clin Oncol 1991, 9:2091-2094. Swedish Melanoma Study Group.
64. Vrouenraets B.C., Nieweg O.E., Kroon B.B. Thirty-five years of isolated limb perfusion for melanoma: indications and results. Br J Surg 1996, 83:1319-1328.
65. Fraker D.L., Alexander H.R., Ross M. A phase III trial of isolated limb perfusion for extremity melanoma comparing melphalan alone versus melphalan plus tumor necrosis factor (TNF) plus interferon gamma (IFN). Ann Surg Oncol 2002, 9:S8.
66. Cornett W.R., McCall L.M., Petersen R.P., et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 2006, (24):4196-4201.
67. Grunhagen D.J., Brunstein F., Graveland W.J., et al. One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases. Ann Surg 2004, 240:939-947. [Discussion 947-8].
68. Grunhagen D.J., van Etten B., Brunstein F., et al. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure. Ann Surg Oncol 2005, 12:609-615.
69. Noorda E.M., Vrouenraets B.C., Nieweg O.E., et al. Isolated limb perfusion: what is the evidence for its use?. Ann Surg Oncol 2004, 11:837-845.
70. Noorda E.M., Vrouenraets B.C., Nieweg O.E., et al. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion. Eur J Surg Oncol 2006, 32:318-324.
71. Vaglini M., Belli F., Ammatuna M., et al. Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose alpha-tumor necrosis factor, gamma-interferon, and melphalan. Cancer 1994, 73:483-492.
72. Noorda E.M., Vrouenraets B.C., Nieweg O.E., et al. Isolated limb perfusion for unresectable melanoma of the extremities. Arch Surg 2004, 139:1237-1242.
73. Rossi C.R., Foletto M., Mocellin S., et al. Hyperthermic isolated perfusion with low-dose TNFalpha and doxorubicin in patients with locally advanced soft tissue limb sarcomas. J Chemother 2004, 16(Suppl 5):58-61.
74. De Wilt J.H., Thompson J.F. Is there a role for isolated limb perfusion with tumor necrosis factor in patients with melanoma?. Ann Surg Oncol 2004, 11:119-121.
75. Lejeune F.J., Ruegg C., Lienard D. Clinical applications of TNF-alpha in cancer. Curr Opin Immunol 1998, 10:573-580.
76. Lienard D., Eggermont A.M., Koops H.S., et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 1999, 9:491-502.
77. Knorr C., Meyer T., Janssen T., et al. Hyperthermic isolated limb perfusion (HILP) in malignant melanoma. Experience with 101 patients. Eur J Surg Oncol 2006, 32:224-227.
78. Balch C.M., Buzaid A.C., Soong S.J., et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001, 19:3635-3648.
79. Grunhagen D.J., de Wilt J.H., Graveland W.J., et al. The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma. Cancer 2006, 106:156-162.
80. Takkenberg R.B., Vrouenraets B.C., van Geel A.N., et al. Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients. J Surg Oncol 2005, 91:107-111.
81. McKinnon J.G. Palliation by perfusion: Is it worth it?. J Surg Oncol 2005, 91:217-218.
82. Lindnér P., Doubrovsky A., Kam P.C., et al. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol 2002, 9:127-136.
83. Kapma M.R., Vrouenraets B.C., Nieweg O.E., et al. Major amputation for intractable extremity melanoma after failure of isolated limb perfusion. Eur J Surg Oncol 2005, 31:95-99.
84. van Horssen R., Rens J.A., Brunstein F., et al. Intratumoural expression of TNF-R1 and EMAP-II in relation to response of patients treated with TNF-based isolated limb perfusion. Int J Cancer 2006, 119:1481-1490.
85. Klaase J.M., Kroon B.B., van Geel A.N., et al. A retrospective comparative study evaluating the results of a single-perfusion versus double-perfusion schedule with melphalan in patients with recurrent melanoma of the lower limb. Cancer 1993, 71:2990-2994.
86. Noorda E.M., Vrouenraets B.C., Nieweg O.E., et al. Long-term results of a double perfusion schedule using high dose hyperthermia and melphalan sequentially in extensive melanoma of the lower limb. Melanoma Res 2003, 13:395-399.
87. Noorda E.M., Vrouenraets B.C., Nieweg O.E., et al. Isolated limb perfusion in regional melanoma. Surg Oncol Clin N Am 2006, 15:373-384.
88. Hill S., Thomas J.M. Use of the carbon dioxide laser to manage cutaneous metastases from malignant melanoma. Br J Surg 1996, 83:509-512.
89. Feldman A.L., Alexander H.R., Bartlett D.L., et al. Management of extremity recurrences after complete responses to isolated limb perfusion in patients with melanoma. Ann Surg Oncol 1999, 6:562-567.
90. Wood B.C., Kleinpeter K.P., Levine E.A. Treatment of in-transit metastases from Merkel cell carcinoma with isolated hyperthermic limb perfusion. Am Surg 2007, 73:1291-1292.
91. Paramo J.C., Benavides C., Tang L.W., et al. Complete remission of previously intractable peripheral cutaneous T-cell lymphoma of the lower extremity using isolated hyperthermic limb perfusion with melphalan (1-phenylalanine mustard). Cancer Invest 2004, 22:545-549.
92. Grunhagen D.J., de Wilt J.H., Verhoef C., et al. TNF-based isolated limb perfusion in unresectable extremity desmoid tumours. Eur J Surg Oncol 2005, 31:912-916.
93. Jansen R.F., van Geel B.N., van der Zee J., et al. Intractable cutaneous non-Hodgkin's lymphoma of the lower limb. Complete remission after sequential regional isolated hyperthermic perfusion and perfusion with 1-phenylalanine-mustard (melphalan, L-PAM). Cancer 1989, 64:392-395.
94. Noorda E.M., Vrouenraets B.C., Nieweg O.E., et al. Isolated limb perfusion with melphalan for femoral metastases of breast cancer: case report. J Surg Oncol 2002, 81:209-212.
95. Kam P.C., Thompson J.F., May J. Isolated limb perfusion with urokinase in the treatment of extensive vascular thrombosis of the lower limbs. Perfusion 1994, 9:399-404.
96. Ali A.T., Kalapatapu V.R., Bledsoe S., et al. Percutaneous isolated limb perfusion with thrombolytics for severe limb ischemia. Vasc Endovasc Surg 2005, 39:491-497.
97. Grootenboers M.J., Heeren J., van Putte B.P., et al. Isolated lung perfusion for pulmonary metastases, a review and work in progress. Perfusion 2006, 21:267-276.
98. Miao N., Pingpank J.F., Alexander H.R., et al. Percutaneous hepatic perfusion in patients with metastatic liver cancer: anesthetic, hemodynamic, and metabolic considerations. Ann Surg Oncol 2008, 15:815-823.
99. Wanebo H.J., Chung M.A., Levy A.I., et al. Preoperative therapy for advanced pelvic malignancy by isolated pelvic perfusion with the balloon-occlusion technique. Ann Surg Oncol 1996, 3:295-303.
100. Wanebo H.J., DiSiena M., Begossi G., et al. Isolated chemotherapeutic perfusion of pelvis as neoadjuvant or palliative therapy for advanced cancer of the rectum. Ann Surg Oncol 2008, 15:1107-1116.
101. Eggermont A.M., Schraffordt Koops H., Klausner J.M., et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996, 224:756-764. [Discussion 764-5].
102. Grunhagen D.J., de Wilt J.H., Graveland W.J., et al. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer 2006, 106:1776-1784.
103. van Etten B., Eggermont A.M., van Tiel S.T., et al. Gene therapy in in vivo isolated perfusion models. Curr Gene Ther 2005, 5:195-202.
104. van Horssen R., Ten Hagen T.L., Eggermont A.M. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 2006, 11:397-408.
105. Hoving S., Brunstein F., Aan de Wiel-Ambagtsheer G., et al. Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats. Cancer Res 2005, 65:4300-4308.
106. Brunstein F., Hoving S., Aan de Wiel-Ambagtsheer G., et al. Decreased response rates by the combination of histamine and IL-2 in melphalan-based isolated limb perfusion. Cancer Immunol Immunother 2007, 56:573-580.
107. Jastrzebski T., Sommer A., Swierblewski M., et al. Possibilities of improving the parameters of hyperthermia in regional isolated limb perfusion using epidural bupivacaine and accurate temperature measurement of the three layers of limb tissue. Melanoma Res 2006, 16:249-257.
108. Grubbs E.G., Ueno T., Abdel-Wahab O., et al. Modulation of resistance to regional chemotherapy in the extremity melanoma model. Surgery 2004, 136:210-218.
109. Grubbs E.G., Abdel-Wahab O., Cheng T.Y., et al. In-transit melanoma: the role of alkylating-agent resistance in regional therapy. J Am Coll Surg 2004, 199:419-427.
110. Pontes L., Lopes M., Ribeiro M., et al. Isolated limb perfusion with fotemustine after chemosensitization with dacarbazine in melanoma. Melanoma Res 1997, 7:417-419.
111. Rossi C.R., Lejeune F.J., Pontes L., et al. Phase I-II study on isolation antiblastic fotemustine perfusion after dacarbazine chemosensitization for advanced melanoma of the extremities. Melanoma Res 2003, 13:293-297.
112. Bonenkamp J.J., Thompson J.F., de Wilt J.H., et al. Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence. Eur J Surg Oncol 2004, 30:1107-1112.
113. Karakousis C.P., Kanter P.M., Lopez R., et al. Modes of regional chemotherapy. J Surg Res 1979, 26:134-141.
114. Bland K.I., Kimura A.K., Brenner D.E., et al. A phase II study of the efficacy of diamminedichloroplatinum (cisplatin) for the control of locally recurrent and intransit malignant melanoma of the extremities using tourniquet outflow-occlusion techniques. Ann Surg 1989, 209:73-80.
115. Karakousis C.P., Kanter P.M., Park H.C., et al. Tourniquet infusion versus hyperthermic perfusion. Cancer 1982, 49:850-858.
116. Thompson J.F., Kam P.C., Waugh R.C., et al. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol 1998, 14:238-247.
117. Thompson J.F., Waugh R.C., Saw R.P.M., et al. Isolated limb infusion with melphalan for recurrent limb melanoma: a simple alternative to isolated limb perfusion. Reg Cancer Treat 1994, 7:188-192.
118. Kroon H.M., Moncrieff M., Kam P.C., et al. Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol 2008, 15:3003-3013.
119. Minor D.R., Allen R.E., Alberts D., et al. A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma. Cancer 1985, 55:2638-2644.
120. Brady M.S., Brown K., Patel A., et al. A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Ann Surg Oncol 2006, 13:1123-1129.
121. Vrouenraets B.C., Klaase J.M., Nieweg O.E., et al. Toxicity and morbidity of isolated limb perfusion. Semin Surg Oncol 1998, 14:224-231.
122. Kroon H.M., Moncrieff M., Kam P.C., et al. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin-D in melanoma patients. Ann Surg Oncol 2009, 16:1184-1192.
123. Hegazy M.A., Kotb S.Z., Sakr H., et al. Preoperative isolated limb infusion of doxorubicin and external irradiation for limb-threatening soft tissue sarcomas. Ann Surg Oncol 2007, 14:568-576.
124. Moncrieff M.D., Kroon H.M., Kam P.C., et al. Isolated limb infusion for advanced soft tissue sarcoma of the extremity. Ann Surg Oncol 2008, 15:2749-2756.
125. Damian D.L., Barnetson R.S., Rose B.R., et al. Treatment of refractory hand warts by isolated limb infusion with melphalan and actinomycin D. Australas J Dermatol 2001, 42:106-109.
126. Damian D.L., Barnetson R.S., Thompson J.F. Treatment of refractory chromomycosis by isolated limb infusion with melphalan and actinomycin D. J Cutan Med Surg 2006, 10:48-51.
127. Elhassadi E., Egan E., O'Sullivan G., et al. Isolated limb infusion with cytotoxic agent for treatment of localized refractory cutaneous T-cell lymphoma. Clin Lab Haematol 2006, 28:279-281.
128. Marsden J., Samarasinghe V., Duddy M., et al. Regional chemotherapy for inoperable limb cancer using isolated limb infusion. Br J Dermatol 2008, 159(S1):10.
129. Kroon H.M., Lin D.Y., Kam P.C., et al. Safety and efficacy of isolated limb infusion with cytotoxic drugs in elderly patients with advanced locoregional melanoma. Ann Surg 2009, 249:1008-1013.
130. Beasley G.M., Petersen R.P., Yoo J., et al. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol 2008, 15:2195-2205.
131. Cassumbhoy R., Pitman A.G. Isolated limb infusion for local control of lower limb melanoma: radiologic aspects. Australas Radiol 2007, 51:543-549.
132. Thompson J.F., Kam P.C. Isolated limb infusion for melanoma: a simple but effective alternative to isolated limb perfusion. J Surg Oncol 2004, 88:1-3.
133. Thompson J.F., Kam P.C.A., de Wilt J.H.W., et al. Isolated limb infusion for melanoma. Textbook of Melanoma 2004, 429-437. Martin Dunitz, London. J.F. Thompson, D.L. Morton, B.B. Kroon (Eds.).
134. Organization W.H. WHO Handbook for Reporting Results of Cancer Treatments (WHO Offset Publication Number 48). Geneva: World Health Organization 1979.
135. Manusama E.R., Nooijen P.T., Stavast J., et al. Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat. Br J Surg 1996, 83:551-555.
136. Pfeiffer T., Krause U., Thome U., et al. Tissue toxicity of doxorubicin in first and second hyperthermic isolated limb perfusion-an experimental study in dogs. Eur J Surg Oncol 1997, 23:439-444.
137. Ueno T., Ko S.H., Grubbs E., et al. Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine. Mol Cancer Ther 2006, 5:732-738.
138. Yoshimoto Y., Augustine C.K., Yoo J.S., et al. Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents. Mol Cancer Ther 2007, 6:1492-1500.
139. Ko S.H., Ueno T., Yoshimoto Y., et al. Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity. Clin Cancer Res 2006, 12:289-297.
140. Green J.A., Vistica D.T., Young R.C., et al. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res 1984, 44:5427-5431.
141. Suzukake K., Vistica B.P., Vistica D.T. Dechlorination of L-phenylalanine mustard by sensitive and resistant tumor cells and its relationship to intracellular glutathione content. Biochem Pharmacol 1983, 32:165-167.
142. Tyler D.S., Yoshimoto Y., Grubbs E., et al. Novel strategies to overcome chemoresistance in regional melanoma therapy by systemic modulation of tumor proteins. Melanoma Res 2006, 16:S100.
143. Roberts M.S., Wu Z.Y., Siebert G.A., et al. Saturable dose-response relationships for melphalan in melanoma treatment by isolated limb infusion in the nude rat. Melanoma Res 2001, 11:611-618.
144. Wu Z.Y., Smithers B.M., Parsons P.G., et al. The effects of perfusion conditions on melphalan distribution in the isolated perfused rat hindlimb bearing a human melanoma xenograft. Br J Cancer 1997, 75:1160-1166.
145. Scott R.N., Kerr D.J., Blackie R., et al. The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma. Br J Cancer 1992, 66:159-166.
146. Wu Z.Y., Smithers B.M., Roberts M.S. Melphalan dosing regimens for management of recurrent melanoma by isolated limb perfusion: application of a physiological pharmacokinetic model based on melphalan distribution in the isolated perfused rat hindlimb. Melanoma Res 1997, 7:252-264.
147. Wu Z., Roberts M.S., Parsons P.G., et al. Isolated limb perfusion with melphalan for human melanoma xenografts in the hindlimb of nude rats: a surviving animal model. Melanoma Res 1997, 7:19-26.
148. Klaase J.M., Kroon B.B., Beijnen J.H., et al. Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb. Br J Cancer 1994, 70:151-153.
149. Thompson J.F., Siebert G.A., Anissimov Y.G., et al. Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies. Br J Cancer 2001, 85:157-165.
150. Roberts M.S., Wu Z.Y., Siebert G.A., et al. Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy. Melanoma Res 2001, 11:423-431.
151. Thompson J.F., Ramzan I., Kam P.C.A., et al. Pharmacokinetics of melphalan during isolated limb infusion for melanoma. Reg Cancer Treat 1996, 9:13-16.
152. Benckhuijsen C., Kroon B.B., van Geel A.N., et al. Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol 1988, 14:157-163.
153. Parsons P.G., Carter F.B., Morrison L., et al. Mechanism of melphalan resistance developed in vitro in human melanoma cells. Cancer Res 1981, 41:1525-1534.
154. Norda A., Loos U., Sastry M., et al. Pharmacokinetics of melphalan in isolated limb perfusion. Cancer Chemother Pharmacol 1999, 43:35-42.
155. Lai D.T.M., Ingvar C., Thompson J.F. The value of monitoring serum creatine phosphokinase values following hyperthermic isolated limb perfusion for melanoma. Reg Cancer Treat 1993, 6:36-39.
156. Vrouenraets B.C., Hart G.A., Eggermont A.M., et al. Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. J Am Coll Surg 1999, 188:522-530.
157. Mian R., Henderson M.A., Speakman D., et al. Isolated limb infusion for melanoma: a simple alternative to isolated limb perfusion. Can J Surg 2001, 44:189-192.
158. Chaplin D.J., Acker B., Olive P.L. Potentiation of the tumor cytotoxicity of melphalan by vasodilating drugs. Int J Radiat Oncol Biol Phys 1989, 16:1131-1135.
159. Skarsgard L.D., Skwarchuk M.W., Vinczan A., et al. The cytotoxicity of melphalan and its relationship to pH, hypoxia and drug uptake. Anticancer Res 1995, 15:219-223.
160. Kroon B.B. Regional isolation perfusion in melanoma of the limbs; accomplishments, unsolved problems, future. Eur J Surg Oncol 1988, 14:101-110.
161. De Vita S.T. Principles of cancer management: chemotherapy. Cancer Principles and Practice of Oncology 1997, 333-348. Lippincott, Philadelphia. S.T. DeVita, S. Hellman, S.A. Rosenberg (Eds.).
162. Lindner P., Thompson J.F., De Wilt J.H., et al. Double isolated limb infusion with cytotoxic agents for recurrent and metastatic limb melanoma. Eur J Surg Oncol 2004, 30:433-439.
163. Kroon H.M., Lin D.-Y., Moncrieff M., et al. Efficacy of repeat isolated limb infusion with melphalan and actinomycin-D for recurrent limb melanoma. Cancer 2008, 115:1932-1940.
164. Klop W.M., Vrouenraets B.C., van Geel B.N., et al. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs. J Am Coll Surg 1996, 182:467-472.
165. Gutman M., Sofer D., Lev-Chelouche D., et al. Synergism of tumor necrosis factor-alpha and melphalan in systemic and regional administration: animal study. Invasion Metastasis 1997, 17:169-175.
166. Nooijen P.T., Manusama E.R., Eggermont A.M., et al. Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study. Br J Cancer 1996, 74:1908-1915.
167. Hoekstra H.J., van Ginkel R.J. Hyperthermic isolated limb perfusion in the management of extremity sarcoma. Curr Opin Oncol 2003, 15:300-303.
168. Noorda E.M., Vrouenraets B.C., Nieweg O.E., et al. Safety and efficacy of isolated limb perfusion in elderly melanoma patients. Ann Surg Oncol 2002, 9:968-974.
169. Thompson J.F., Gianoutsos M.P. Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 1992, 16:227-233.
170. Klaase J.M., Kroon B.B., van Geel A.N., et al. Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery 1994, 115:39-45.
171. Kettelhack C., Kraus T., Hupp T., et al. Hyperthermic limb perfusion for malignant melanoma and soft tissue sarcoma. Eur J Surg Oncol 1990, 16:370-375.
172. Lingam M.K., Byrne D.S., Aitchison T., et al. A single centre's 10 year experience with isolated limb perfusion in the treatment of recurrent malignant melanoma of the limb. Eur J Cancer 1996, 32A:1668-1673.
173. Aloia T.A., Grubbs E., Onaitis M., et al. Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response. Arch Surg 2005, 140:1115-1120.
174. Cavaliere R., Cavaliere F., Deraco M., et al. Hyperthermic antiblastic perfusion in the treatment of stage IIIA-IIIAB melanoma patients. Comparison of two experiences. Melanoma Res 1994, 4(Suppl 1):5-11.
175. Di Filippo F., Anza M., Rossi C.R., et al. The application of hyperthermia in regional chemotherapy. Semin Surg Oncol 1998, 14:215-223.
176. Klaase J.M., Kroon B.B., van Geel A.N., et al. Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion. J Am Coll Surg 1994, 178:564-572.
177. Zogakis T.G., Bartlett D.L., Libutti S.K., et al. Factors affecting survival after complete response to isolated limb perfusion in patients with in-transit melanoma. Ann Surg Oncol 2001, 8:771-778.
178. Hoekstra H.J., Schraffordt Koops H., de Vries L.G., et al. Toxicity of hyperthermic isolated limb perfusion with cisplatin for recurrent melanoma of the lower extremity after previous perfusion treatment. Cancer 1993, 72:1224-1229.
179. Bartlett D.L., Ma G., Alexander H.R., et al. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics. Cancer 1997, 80:2084-2090.
180. Barbour A.P., Thomas J., Suffolk J., et al. Isolated limb infusion for malignant melanoma: predictors of response and outcome. Ann Surg Oncol 2009, 16:3463-3472.
181. Beasley G.M., Caudle A., Petersen P.R., et al. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg 2009, 208:706-715.